Milestone Scientific (MLSS) Q2 2026 earnings review
Medical Segment Ignites Revenue, But Liquidity Clock is Ticking
Milestone broke out of its revenue stagnation with a 22.3% YoY jump to $2.8 million in Q2. The turnaround thesis is finally materializing, driven by a 231% surge in CompuFlo medical sales and a $500k international dental order. Management maintained strict cost discipline, cutting operating expenses by 4.2% YoY. However, gross margins compressed to 67.2% due to tariff pressures, and with only $2.1 million in cash remaining against a $1.1 million quarterly net loss, the margin of error to reach management's early-2027 breakeven target is exceptionally narrow.
🐂 Bull Case
CompuFlo revenue accelerated by 231% YoY. With Medicare reimbursement ($325) active in 13 states and a new distribution deal for VA/DoD hospitals, the commercialization pipeline is rapidly maturing.
Management continues to execute on its pledge to trim waste. H1 2026 operating expenses fell 20.5% YoY, proving that top-line growth is not being bought with unsustainable marketing spend.
🐻 Bear Case
Ending Q2 with just $2.06 million in cash against a quarterly net loss of $1.06 million leaves a precarious runway, elevating the risk of highly dilutive capital raises before the 2027 breakeven goal.
Management explicitly warned that $500,000 of Q2's revenue came from one-off international orders that will not repeat in Q3, setting up a sharp sequential deceleration.
⚖️ Verdict: ⚪
Neutral. The commercial execution on the CompuFlo strategy is highly encouraging and validates the turnaround thesis. However, shrinking gross margins from tariffs and a dangerously thin cash runway prevent a fully bullish stance until breakeven is secured.
Key Themes
CompuFlo Adoption is Accelerating
The medical business is transforming from a concept into a primary growth engine. CompuFlo revenue surged 231% YoY, supported by successful billing under CPT 0777T ($325 reimbursement) and the first paid workers' compensation claim. Clinical validation was bolstered by a University of Texas Medical Branch study showing a 91% reduction in complication odds during spinal cord stimulator implantation, giving the sales force a potent new tool to drive academic and hospital adoption.
Strategic Entry into Federal Healthcare
Subsequent to quarter-end, Milestone signed a distribution agreement with Red One Medical to target the VA, DoD, and Defense Health Agency. This opens a massive, centralized addressable market (18 million beneficiaries) that operates largely outside traditional commercial payer reimbursement friction, providing a secondary avenue to rapidly scale medical sales.
Unyielding Operating Expense Discipline
Management is maintaining its tight grip on the P&L. Q2 operating expenses declined 4.2% YoY to $2.97 million, and H1 expenses are down an impressive 20.5% YoY. Decreases in consulting, professional fees, and R&D offset necessary investments in stock-based compensation and warehousing. This structural cost reduction is vital for translating any revenue growth into a narrowed cash burn.
Tariffs Compressing Gross Margins
A negative macro factor has emerged: gross margin compressed to 67.2% in Q2 from 69.6% a year ago, and down sharply from 72.3% in Q1 2026. Management explicitly cited tariffs imposed on imported products and components as a primary headwind. This contradicts the positive narrative of operating leverage, as higher sales volumes are currently generating diminishing unit profitability.
Cash Runway Leaves Zero Room for Error
Despite narrowing operating losses, the balance sheet remains a critical vulnerability. The company holds $2.06 million in cash and cash equivalents. With an operating loss of $1.06 million this quarter, the current trajectory suggests less than two quarters of runway unless working capital is managed flawlessly or revenue spikes violently. The early-2027 cash flow breakeven target looks financially distant without a bridge.
Q3 Growth Illusion Warning
While the 22.3% YoY revenue jump is a headline win, the underlying data points to an impending sequential reversal. Management frankly stated that $500,000 of the $2.8 million Q2 revenue came from two large international orders that will not recur in Q3. Combined with standard Q3 seasonality, investors must brace for a significant sequential revenue deceleration next quarter.
Other KPIs
Down 20.5% YoY from $6.74 million in H1 2025. This metric showcases the success of the CEO's structural turnaround program initiated last year, drastically lowering the revenue threshold required for the company to eventually turn profitable.
A vast improvement from the -$3.47 million loss in H1 2025. This halving of the net loss run-rate confirms that the company is effectively plugging the leaks that historically ravaged shareholder value, though liquidity remains tight.
Guidance
Stable. Management reaffirmed its full-year outlook. Achieving the midpoint ($10.0M) requires approximately $5.0M in H2 2026 revenue, implying roughly 11% YoY growth over FY25's $9.0M base.
Stable. The company continues to target cash flow breakeven in roughly two to three quarters. Achieving this depends heavily on CompuFlo sales scaling rapidly to offset Q3 seasonality and current margin pressures.
Key Questions
Tariff Mitigation Strategy
Gross margins dropped by over 200 basis points YoY, largely blamed on tariffs. What specific supply chain actions or pricing adjustments are being implemented to prevent further erosion of unit economics?
Bridging the Cash Gap
With roughly $2.1 million in cash and an expectation for a seasonally slower Q3 lacking $500k in one-off orders, how will management fund operations through the end of the year without raising dilutive capital before the early-2027 breakeven point?
Red One Medical Economics
How should investors model the financial impact of the new DoD/VA distribution agreement? What is the expected sales cycle length for these federal organizations compared to commercial pain clinics?
Dental Ambassador Program ROI
Last quarter you noted that the new Dental Ambassador program was in its infancy and operating under the Pareto principle. Did this program meaningfully contribute to Q2's base business performance, and what are the KPIs for H2?